高级检索
当前位置: 首页 > 详情页

Tumor-stroma ratio (TSR) in non-small cell lung cancer (NSCLC) patients after lung resection is a prognostic factor for survival

文献详情

资源类型:
机构: [1]Sun Yat Sen Univ, Dept Thorac Surg, Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China; [2]Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China; [3]Sun Yat Sen Univ, Dept Pathol, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China; [4]Hangzhou Normal Univ, Dept Med Oncol, Affiliated Hosp, Hangzhou 310015, Zhejiang, Peoples R China; [5]Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China
出处:
ISSN:

关键词: Non-small cell lung cancer (NSCLC) tumor-stroma ratio (TSR) prognosis tumor microenvironment

摘要:
Background: In recent years, the tumor-stroma ratio (TSR) has been considered to a new and independent predictive variable for the prognosis of some kinds of neoplasms. The objective of this study was to assess the prognostic significance of the TSR in non-small cell lung cancer (NSCLC). Methods: A cohort of 261 NSCLC patients who underwent radical surgery of lung cancer were included in the present study. Two independent observers visually estimated the TSR on hematoxylin-eosin (H&E) stained tissue pathological slices. According to the proportion of stroma >= 50% or <50%, We separate the patients into two groups: those with stroma-poor and those with stroma-rich tumors. Results: Both univariate and multivariate analyses disclosed that the TSR was associated with overall survival (OS) [hazard ratio (HR), 1.741; 95% confidence intervals (CI), 1.040-2.913 and HR, 1.904; 95% CI, 1.132-3.202, respectively]. The HR values for disease-free survival (DFS) were 1.795 (95% CI, 1.073-3.005) and 2.034 (95% CI, 1.210-3.420). The OS and DFS of patients with stroma-poor tumors were better than those with stroma-rich tumors. Conclusions: These results demonstrated that the TSR is a new prognostic factor for NSCLC. Stromapoor tumors were associated with longer disease-free period and better prognosis than were stroma-rich tumors in NSCLC patients. The TSR may contribute to the development of individualized treatment for NSCLC in the future.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类 | 4 区 医学
小类 | 4 区 呼吸系统
最新[2023]版:
大类 | 3 区 医学
小类 | 4 区 呼吸系统
第一作者:
第一作者机构: [1]Sun Yat Sen Univ, Dept Thorac Surg, Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China; [2]Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China;
通讯作者:
通讯机构: [1]Sun Yat Sen Univ, Dept Thorac Surg, Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China; [2]Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China;
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43374 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号